Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Lodges Patent for Major Septic Shock Opportunity (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce lodgement of an international patent application aimed at protecting the use of Veyonda (idronox...read more

Noxopharm IONIC Immuno-Oncology Trial Commences (ASX:NOX)

Highlights: Ethics Approval received for IONIC-1 clinical trial, with trial to commence immediately in Australian hospitals IONIC-1 to test combination of Veyonda® with blockbuster Bristol...read more

NOXCOVID Trial Advances to Final Stage (ASX:NOX)

Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial Top dose of 1800 mg Veyonda daily to be used in final patient cohort Tests on blood ...read more

Noxopharm: Updated Corporate Presentation February-March 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides to shareholders and the market generally the attached corporate presentation ahead of a series of global vir...read more

Noxopharm Announces LuPIN Trial Survival Outcome Confirmed by Conference Presentation (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide a more detailed summary of the data from the LuPIN study that was formally presented to the Ameri...read more

Noxopharm Announces Global Conference To Hear of Major Survival Benefit in Prostate Cancer Patients (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to report the publication in abstract form of the latest survival data from the LuPIN study ahead of a forma...read more

Noxopharm Announces NOXCOVID Study Advances (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), announces that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the ...read more

Noxopharm Shareholder Update 2021 (ASX:NOX)

Australian clinical stage drug development company, Noxopharm Limited (ASX:NOX), provides this shareholder update as a summary of R&D progress in 2020 and a guide to what 2021 is expected to hol...read more

Noxopharm Announces PreClinical Breakthrough Discovery Set to Expand Noxopharm Pipeline (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce what it regards as a major breakthrough in anti-cancer drug discovery. Noxopharm scientists h...read more

Noxopharm Completes A$23 million Placement to Fund Clinical Studies (ASX:NOX)

Highlights: - Noxopharm successfully raises A$23 million via a Placement, with cornerstone institutional investors coming from Australia, Hong Kong and the USA - Funds raised will drive two new ...read more

Noxopharm - Independent Discovery Validates DARRT Cancer Therapy (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to note that a recent discovery by a major U.S. university group significantly validates the Company’s...read more

Noxopharm - Veyonda To Be Tested In Combination With Opdivo In Trial (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that NOX have joined with Principal Investigator, Professor Paul De Souza, and three Sydney hosp...read more

Noxopharm Announces Dedicated Septic Shock Company Established (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce a partnership with Hudson Institute of Medical Research (‘Hudson Institute’) and a c...read more

Noxopharm - First COVID-19 Patient Treated in Veyonda Study (ASX:NOX)

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the enrolment and treatment of the first patient into the Phase 1 NOXCOVID-1 study examini...read more

Noxopharm Announces Veyonda COVID-19 Study Approved For Immediate Start (ASX:NOX)

Australian drug development companyNoxopharm Limited (ASX: NOX) today announces the commencement of a clinical study of Veyonda® in COVID-19 patients. Following review by expert panels, official...read more

Viewing: 1 - 15 of 169 Previous | Next